Sep 21, 2018

Family Reach Donation Impact Fact Sheet

This fact sheet provides an overview of the gift, including the when, why and how we will measure impact of this donation. It also shows the locations for expansion.
Sep 21, 2018

AbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families

NORTH CHICAGO, Ill., Sept. 21, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization's efforts to alleviate the financial burden of cancer on pediatric patients and families across the United States. This donation, the largest contribution received by Family Reach, was announced at the Biden Cancer Summit in Washington, D.C. Hosted by Vice President Joe Biden and Dr. Jill Biden, the Biden Cancer Summit aims to drive a sense of urgency in developing and implementing new solutions, to build a cancer community that is connected, coordinated, and collaborative, and to showcase the broad range of unique cancer experiences and stories that together comprise the collective cancer narrative.

Sep 21, 2018

AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

NORTH CHICAGO, Ill., Sept. 21, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO® (venetoclax tablets) in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy. The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which will deliver its final decision, valid in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.

Sep 17, 2018

AbbVie to Host Third-Quarter 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Sept. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2018 financial results on Friday, November 2 2018, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Sep 13, 2018

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis.1,2 Results from a pre-specified, interim analysis from the Phase 2b dose-ranging study showed that treatment with upadacitinib 7.5 mg, 15 mg or 30 mg resulted in greater improvements in itch and skin lesions, with statistically significant differences observed versus placebo at week 32.1 Additionally, results from a further analysis of a subset of patients showed that upadacitinib improved patient-reported itch and impact on sleep due to atopic dermatitis in patients receiving upadacitinib (30 mg, once-daily) compared to placebo at week 16.2 Data from these two analyses will be presented today at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

Sep 13, 2018

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in adult patients with moderate to severe plaque psoriasis. Across all three trials, patients reported significant improvements in health-related quality of life, mental health and work productivity measures when treated with risankizumab.1,2 Data from these studies will be presented at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris. Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

Sep 11, 2018

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label

NORTH CHICAGO, Ill., Sept. 11, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA® (venetoclax tablets) in combination with rituximab to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.

Sep 07, 2018

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 7, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share.

Sep 05, 2018

Public Voting is Open for the 2018 AbbVie CF Scholarship Thriving Student Awards, Given to Two Exceptional Students Living with Cystic Fibrosis

NORTH CHICAGO, Ill., Sept. 5, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced its annual call for the public to vote for students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system, as part of its 2018 Thriving Student Scholarship. Scholarships totaling $25,000 each – the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship – will be awarded to two deserving students.

Sep 04, 2018

AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress

NORTH CHICAGO, Ill., Sept. 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new data across investigational medicines and HUMIRA® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12-16, in Paris.